Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum
tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily
oral dose), given in combination with trastuzumab administered through the vein, in patients
with HER2-amplified Metastatic Breast Cancer that has gotten worse after prior therapy with
ado-trastuzumab emtansine (T-DM1).